Obesity drugs battle prompts massive M&A wave in pharma
America’s latest skirmish over drug prices has placed a new class of weight-loss and diabetes medicines squarely in the political and financial crosshairs.
America’s latest skirmish over drug prices has placed a new class of weight-loss and diabetes medicines squarely in the political and financial crosshairs.
Developed by Moore-Wilson